Clinical Trials Logo

Thoracoabdominal Aortic Aneurysm clinical trials

View clinical trials related to Thoracoabdominal Aortic Aneurysm.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05954793 Recruiting - Clinical trials for Thoracoabdominal Aortic Aneurysm

A PMCF Study in Patients With Thoracoabdominal Aortic Aneurysms Treated With E-nside TAAA Multibranch Stent Graft System (INNER-B-APAC)

Start date: January 1, 2022
Phase:
Study type: Observational [Patient Registry]

The INNER-B-APAC post-market clinical follow-up study is undertaken to demonstrate the safety and clinical performance of the E-nside TAAA Multibranch Stent Graft System used in endovascular treatment of patients with thoracoabdominal aortic aneurysms.

NCT ID: NCT05896397 Recruiting - Clinical trials for Thoracoabdominal Aortic Aneurysm

European Aortic Data Collection Project

EADC
Start date: May 31, 2023
Phase:
Study type: Observational

The purpose of this study is to evaluate the safety and performance of Cook's various Custom-Made Stent-graft Devices (CMD) used for endovascular treatment of the aorta and related diseases by collecting information on the real-world use of the devices. The study results will be used to support the continuation of the CMDs on the market. In addition, the study will support the manufacturers obligation for post market product surveillance as well as Cook's technology development.

NCT ID: NCT05758844 Recruiting - Clinical trials for Thoracoabdominal Aortic Aneurysm

The Safe-line Technique as Additional Attempt to Mitigate Spinal Cord Ischemia After Endovascular Exclusion of TAAA

Safe-line-tech
Start date: April 30, 2023
Phase:
Study type: Observational [Patient Registry]

To assess safety and feasebility of the "safe-line" technique in a multicenter international collaboration.

NCT ID: NCT05339061 Recruiting - Clinical trials for Thoracoabdominal Aortic Aneurysm

Physician Modified Endograft For Complex Aortic Aneurysm Repair

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

The physician modified endograft is intended for treating complex, pararenal, juxtarenal and thoracoabdominal aortic aneurysms requiring coverage of renal arteries, the superior mesenteric artery or the celiac trunk in high-risk patients who do not have an option for endovascular repair with an FDA approved endograft and have an appropriate anatomy. There will be one investigational site with a total of 40 subjects to be enrolled. Time to complete enrollment will be 24 months and the subject follow-up time will be five years from last subject enrollment. The primary safety endpoint is freedom from major adverse events (MAE) at 30 days or during hospitalization if this exceeds 30 days. The primary effectiveness endpoint is the proportion of study subjects with treatment success at one year. The subjects will be followed at one month, six months, one year, and yearly thereafter for a total period of five years. Subjects will be followed up clinically for life. Clinical exam follow up may be phone or video visit with CT scan evaluation and duplex ultrasound as needed. The proportion of treatment group subjects that achieve and maintain treatment success annually to five years will be investigated.

NCT ID: NCT05224219 Recruiting - Clinical trials for Thoracoabdominal Aortic Aneurysm

Modified Preloaded System for Renal Arteries in Fenestrated Endografting (MPSRA)

MPSRA
Start date: January 1, 2019
Phase:
Study type: Observational

Advanced Endovascular repair of aneurysms and dissections involving thoraco-abdominal (type I-IV) and complex abdominal (juxta and para-renal) aorta is a ground-gaining procedure allowing favorable results in high surgical risk patients. The availability of iliac vessels navigation and the major role of lower leg perfusion in order to decrease the risk of spinal cord ischemia during these complex procedures, led to the development of devices with lower sheaths sizes and to the improvement of the technique with preloaded devices for visceral vessels in order to navigate in hostile anatomies or when an iliac access is not available. The aim of the study is to evaluate in a prospective single center observational setting, the outcomes, safety and efficacy of the modified preloaded system for renal arteries in fenestrated endografting in the routine treatment of paravisceral and thoraco-abdominal aortic pathologies.

NCT ID: NCT05195905 Recruiting - Clinical trials for Thoracoabdominal Aortic Aneurysm

PMEG for Repair of Pararenal and Thoracoabdominal Aortic Aneurysm

Start date: June 6, 2023
Phase: N/A
Study type: Interventional

The primary objective is to evaluate the safety and effectiveness of surgeon modified endografts for the treatment of pararenal and thoracoabdominal aortic pathology in patients who are not candidate for traditional open repair due to comorbid issues and their anatomy is not amenable to commercially available endografts.

NCT ID: NCT04746677 Recruiting - Clinical trials for Abdominal Aortic Aneurysm

Safety and Efficacy of Endovascular Repair of Complex Aortic Pathology With Physician-modified Endovascular Grafts (PMEGs)

Start date: March 15, 2021
Phase: N/A
Study type: Interventional

The primary objective of this study is to examine the safety and effectiveness of physician-modified endovascular grafts (PMEGs) for endovascular repair of complex aortic pathology in high-risk patients. The study is divided into three study arms based on the subject's aortic pathology: (1) Complex abdominal aortic aneurysm (AAA); (2) Thoracoabdominal aortic aneurysm; and (3) Aortic dissection.

NCT ID: NCT04600089 Recruiting - Postoperative Pain Clinical Trials

Ketamine in Patients Undergoing TEVAR Procedures Receiving NCI

2020Ketamine
Start date: December 8, 2020
Phase: Phase 2
Study type: Interventional

The objective of this study is to identify the opioid-sparing effects, and pain-reduction potential of low dose, sub-dissociative ketamine on patients undergoing thoracic endovascular aortic repair (TEVAR) procedures receiving naloxone continuous infusion (NCI).

NCT ID: NCT04526938 Recruiting - Clinical trials for Thoracoabdominal Aortic Aneurysm

Physician-modified Endovascular Graft for Repair of Complex Thoracoabdominal and Abdominal Aortic Aneurysms

Start date: September 20, 2021
Phase: N/A
Study type: Interventional

The primary objective of this study is to assess the use of a physician-modified Cook Alpha Thoracic Endovascular Graft in the repair of complex aortic aneurysms and thoracoabdominal aortic aneurysms and aneurysms secondary to aortic dissections in high-risk patients having appropriate anatomy. The primary intent of the study is to assess the safety and preliminary effectiveness of the device. Additionally, the study will assess renal function, radiation exposure, and quality of life.

NCT ID: NCT04524247 Recruiting - Frailty Syndrome Clinical Trials

Frailty and Physician Modified Fenestrated Endograft for Thoracoabdominal Aortic Pathologies

Start date: February 23, 2021
Phase: N/A
Study type: Interventional

The primary objective of this single arm, prospective feasibility study, Impact of Frailty on Clinical Outcomes of Patients Treated for Thoracoabdominal and Complex Abdominal Aortic Aneurysms with Physician-Modified Fenestrated and Branched Stent Grafts, is to assess the use of the physician-modified fenestrated/branched endografts to repair thoracoabdominal and complex aortic aneurysms in subjects having appropriate anatomy, at high risks for open repairs. The primary intent of the study is to assess safety and preliminary effectiveness of the device acutely (i.e., treatment success and technical success), at 30 days (i.e., the rate of major adverse events (MAE)) and at 3 months, 6 months, 12 months, and annually to 5 years (i.e., the proportion of treatment group subjects that achieve and maintain treatment success). Additionally, this study will assess the degree of patient frailty before and after the aneurysm repair, as well as the association between the preoperative baseline frailty and clinical outcomes detailed above. This will help improve subject selection in identification of high risk patients who would not only suffer poor clinical outcomes, but also experience decline in their functional status.